Alto Neuroscience (NYSE:ANRO) Stock Price Down 8.3% - Time to Sell?

Key Points

• Alto Neuroscience shares fell 8.3% to $28.24, with trading volume down 79% versus the average session. The stock remains above its 200-day moving average of $25.91 but below its 50-day average of $31.21.
• Analyst sentiment is mixed, though the overall consensus remains “Moderate Buy” with a $37.25 target price. Eight analysts rate the stock Buy, two rate it Hold, and one rates it Sell.
• The clinical-stage biopharmaceutical company beat quarterly earnings expectations, reporting a $0.65 per-share loss versus the estimated $0.73 loss, but analysts expect a larger full-year loss of $2.68 per share.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was down 8.3% during trading on Wednesday . The stock traded as low as $29.02 and last traded at $28.24. Approximately 84,136 shares changed hands during trading, a decline of 79% from the average session volume of 393,136 shares. The stock had previously closed at $30.78.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wedbush raised their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a research note on Thursday, August 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Zacks Research raised shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. BTIG Research upped their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. Finally, Wall Street Zen cut Alto Neuroscience from a "hold" rating to a "sell" rating in a research note on Saturday, September 12th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.25.

Alto Neuroscience Stock Performance

The stock has a market cap of $1.04 billion, a PE ratio of -10.98 and a beta of 1.13. The company has a fifty day moving average price of $31.21 and a 200 day moving average price of $25.91. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. Analysts expect that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANRO. Commodore Capital LP bought a new position in shares of Alto Neuroscience during the fourth quarter valued at about $32,453,000. Perceptive Advisors LLC lifted its holdings in Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock worth $31,762,000 after buying an additional 1,629,027 shares during the period. Spruce Street Capital LP grew its position in shares of Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock worth $29,116,000 after buying an additional 1,102,366 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Alto Neuroscience during the first quarter valued at approximately $11,240,000. Finally, Jennison Associates LLC purchased a new position in shares of Alto Neuroscience during the first quarter valued at approximately $8,687,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto's pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.